Printer Friendly

INNOVET, MATRIX BIOSCIENCE: ANIMAL TESTS CONFIRM ORAL INSULIN; PLAN TO ACCELERATE DEVELOPMENT OF TECHNOLOGY FOR OTHER APPLICATIONS

 INNOVET, MATRIX BIOSCIENCE: ANIMAL TESTS CONFIRM ORAL INSULIN;


PLAN TO ACCELERATE DEVELOPMENT OF TECHNOLOGY FOR OTHER APPLICATIONS
 BOCA RATON, Fla., April 20 /PRNewswire/ -- InnoVet, Inc. (NASDAQ: IVET) and Matrix BioScience have developed a technology that delivered insulin orally in preliminary animal tests conducted by an independent laboratory.
 Insulin that can be taken by mouth, rather than by injection, holds potential benefits for a great number of Americans, many of them children. According to American Diabetes Foundation figures, 700,000 to 1.4 million Americans have insulin-dependent (Type I) diabetes. Currently, 115,000 children must inject insulin every day. The risk of developing insulin-dependent diabetes is higher than virtually all other severe chronic diseases of childhood, the Foundation noted.
 The key to delivering insulin and other therapeutics made of short protein strands (peptides) lies in wrapping the medicine in a molecular envelope so that it is not easily digested and can pass through cell membranes intact. The MicroMatrix Technology ads bio-compatible polymer molecules to insulin to create an oral delivery system. The developers believe that their delivery system can be adapted for many other therapeutics, both human and veterinary, as well as for agricultural applications. "These preliminary animal test results are very encouraging," said Dr. Jesse W. Houdeshell, InnoVet's president. "Based on the success of these tests, we will be accelerating our plans to develop the technology for other applications."
 In addition to allowing insulin to be delivered orally, the new technology also improved insulin activity when injected under the skin. Houdeshell said, "We will be doing additional testing to attempt to demonstrate that our system makes peptides more stable, extends their biological half-life, and reduces or eliminates allergenic responses."
 "Separate studies have shown that the biopolymer and insulin- biopolymer complex have a wide margin of safety in test animals. We are moving quickly to develop products with a number of peptides, using either the oral delivery system or a sustained release parenteral (injectable) system. This new delivery system could have many applications for treating major diseases in both animals and humans," Houdeshell added.
 InnoVet, headquartered in Boca Raton, is dedicated to the research, development and marketing of innovative pharmaceutical and biological products to address the needs of the human health and animal health and agriculture markets. InnoVet manages the research and development of the MicroMatrix Technology and will receive a substantial royalty from Matrix BioScience from the animal health and agricultural uses of the technology.
 Matrix BioScience is also developing unique anti-tumor and anti- viral drugs and synthesizing environmentally safe and biodegradable insecticides. Matrix BioScience acquired the MicroMatrix technology from InnoVet in 1991.
 /delval/
 -0- 4/20/92
 /CONTACT: Diane LeBas or Lois Kaufman, 609-683-9055, both of INFOCUS, or Robert Fuchs of Sunrise Financial Group, 212-593-6483/
 (IVET) CO: InnoVet, Inc.; Matrix BioScience ST: Florida IN: MTC SU: JVN PDT


MP-JS -- PH008 -- 9943 04/20/92 10:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1992
Words:478
Previous Article:MERRIMAC INDUSTRIES ANNOUNCES ACQUISITION OF BTI
Next Article:TERADYNE RELEASES FIRST QUARTER RESULTS


Related Articles
INNOVET ACQUIRES DRA & ASSOCIATES; DRA REACHES AGREEMENT WITH WEIDER TO DEVELOP AND MARKET DIAGNOSTICS FOR FITNESS AND SPORTS NUTRITION MARKET
INNOVET AND MATRIX BIOSCIENCE ANNOUNCE AGREEMENT WITH DU PONT
INNOVET APPOINTS CORPORATE COMMUNICATIONS COUNSEL
INNOVET SUBSIDIARY EARNS SMART AWARD FROM U.K. DEPARTMENT OF TRADE AND INDUSTRY: NEW TECHNOLOGY TO DETECT POTENTIALLY HARMFUL RESIDUES IN MEAT
INNOVET EXPANDS SALES TO ASIA AND LATIN AMERICA
INNOVET ADDS PRODUCTS AND SALES STAFF; SERVES REFERENCE LABORATORIES
INNOVET SELECTS CEO
INNOVET TO SELL BROOKS FEEDS ASSETS
Encelle Caps $5M Series B Financing Round; Company Developing Bioartificial Pancreas for Type I Diabetes.
Latest Generex Test Results Confirm Efficacy of Oral Insulin in Controlling Post-Prandial Hyperglycemia.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters